Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG.

Sci Transl Med. 2016 Mar 2;8(328):328ra28. doi: 10.1126/scitranslmed.aac8228.

2.

Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG.

Mol Ther Methods Clin Dev. 2014 Feb 5;1. pii: 10.

3.

Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG.

Hum Gene Ther Clin Dev. 2013 Sep;24(3):116-26. doi: 10.1089/humc.2013.139.

4.

Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG.

Toxicol Appl Pharmacol. 2013 May 1;268(3):318-30. doi: 10.1016/j.taap.2013.02.001. Epub 2013 Feb 9.

5.

Synthesis and chemistry of bis(triisopropylphosphine) nickel(I) and nickel(0) precursors.

Beck R, Shoshani M, Krasinkiewicz J, Hatnean JA, Johnson SA.

Dalton Trans. 2013 Feb 7;42(5):1461-75. doi: 10.1039/c2dt32008h. Epub 2012 Nov 20.

PMID:
23169546

Supplemental Content

Loading ...
Support Center